188 related articles for article (PubMed ID: 38539473)
1. Follicle-Stimulating Hormone Receptor Expression and Its Potential Application for Theranostics in Subtypes of Ovarian Tumors: A Systematic Review.
Bakker ME; Brink GJ; Poot AJ; Braat AJAT; Jonges GN; Zweemer RP
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539473
[TBL] [Abstract][Full Text] [Related]
2. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
3. Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype.
Perez-Juarez CE; Arechavaleta-Velasco F; Mendez C; Díaz-Cueto L
Med Oncol; 2020 May; 37(7):59. PubMed ID: 32474861
[TBL] [Abstract][Full Text] [Related]
4. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers.
Stouffer RL; Grodin MS; Davis JR; Surwit EA
J Clin Endocrinol Metab; 1984 Sep; 59(3):441-6. PubMed ID: 6086699
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
6. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.
Zheng W; Lu JJ; Luo F; Zheng Y; Feng Yj; Felix JC; Lauchlan SC; Pike MC
Gynecol Oncol; 2000 Jan; 76(1):80-8. PubMed ID: 10620446
[TBL] [Abstract][Full Text] [Related]
7. Androgens improve ovarian follicle function impaired by glucocorticoids through an androgen-IGF1-FSH synergistic effect.
Gao L; Gao H; Wang W
Front Endocrinol (Lausanne); 2022; 13():951928. PubMed ID: 36339442
[TBL] [Abstract][Full Text] [Related]
8. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
9. A follicle-stimulating hormone receptor-targeted near-infrared fluorescent probe for tumor-selective imaging and photothermal therapy.
Liu Q; Pu T; Zhou X; Sun J; Yuan W; Zhang S; Zhang M; Zhang M; Peng J; Li F; Zhang X; Xu C
Mater Today Bio; 2024 Feb; 24():100904. PubMed ID: 38130428
[TBL] [Abstract][Full Text] [Related]
10. Establishment of steroidogenic granulosa cell lines expressing follicle stimulating hormone receptors.
Keren-Tal I; Dantes A; Sprengel R; Amsterdam A
Mol Cell Endocrinol; 1993 Sep; 95(1-2):R1-10. PubMed ID: 8243796
[TBL] [Abstract][Full Text] [Related]
11. A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors.
Kotlar TJ; Young RH; Albanese C; Crowley WF; Scully RE; Jameson JL
J Clin Endocrinol Metab; 1997 Apr; 82(4):1020-6. PubMed ID: 9100567
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Granulosa Cell Tumor in a Postmenopausal Woman: A Case Report and Literature Review.
Dolkar T; Rayapureddy AK; Kadakia N; Bellamkonda A; Kalavar M
Cureus; 2023 Aug; 15(8):e43368. PubMed ID: 37700975
[TBL] [Abstract][Full Text] [Related]
13. Roles of follicle stimulating hormone and sphingosine 1-phosphate co-administered in the process in mouse ovarian vitrification and transplantation.
Wang F; Tian Y; Huang L; Qin T; Ma W; Pei C; Xu B; Han H; Liu X; Pan P; Yu X; Chang Q; Wang Y; Zhang S; Pei X
J Ovarian Res; 2023 Aug; 16(1):173. PubMed ID: 37620938
[TBL] [Abstract][Full Text] [Related]
14. No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors.
Fuller PJ; Verity K; Shen Y; Mamers P; Jobling T; Burger HG
J Clin Endocrinol Metab; 1998 Jan; 83(1):274-9. PubMed ID: 9435455
[TBL] [Abstract][Full Text] [Related]
15. Melan-A (A103) and inhibin expression in ovarian neoplasms.
Yao DX; Soslow RA; Hedvat CV; Leitao M; Baergen RN
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):244-9. PubMed ID: 12966351
[TBL] [Abstract][Full Text] [Related]
16. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.
Zhang Z; Zhu Y; Lai Y; Wu X; Feng Z; Yu Y; Bast RC; Wan X; Xi X; Feng Y
Int J Oncol; 2013 Oct; 43(4):1194-204. PubMed ID: 23921511
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors.
Healy DL; Burger HG; Mamers P; Jobling T; Bangah M; Quinn M; Grant P; Day AJ; Rome R; Campbell JJ
N Engl J Med; 1993 Nov; 329(21):1539-42. PubMed ID: 8413476
[TBL] [Abstract][Full Text] [Related]
18. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.
Dewailly D; Robin G; Peigne M; Decanter C; Pigny P; Catteau-Jonard S
Hum Reprod Update; 2016 Nov; 22(6):709-724. PubMed ID: 27566840
[TBL] [Abstract][Full Text] [Related]
19. Potential role of follicle-stimulating hormone (FSH) and transforming growth factor (TGFβ1) in the regulation of ovarian angiogenesis.
Kuo SW; Ke FC; Chang GD; Lee MT; Hwang JJ
J Cell Physiol; 2011 Jun; 226(6):1608-19. PubMed ID: 20945379
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
